Fundz

Waypoint Bio raises $14.5M in seed funding led by Hummingbird Ventures for in vivo spatial pooled screening technology

PRIVATEJun 28, 2024

Amount Raised

$14.5 Million

Round Type

Seed

New YorkBiotechnologyHealth CareTherapeutics

Investors

Fifty YearsRecode VenturesHummingbird Ventures

Description

Waypoint Bio, a biotechnology company focusing on cell therapies for solid tumors, has secured $14.5 million in seed funding led by Hummingbird Ventures. The company's platform combines spatial biology with pooled screening to enable the engineering of cell therapy designs for historically intractable diseases, such as pancreatic cancer.

Quick answer

Waypoint Bio raised $14.5 Million in a Seed round, dated June 28, 2024. Investors: Fifty Years, Recode Ventures and Hummingbird Ventures. Waypoint Bio is based in New York, New York, United States.

How much did Waypoint Bio raise?
Waypoint Bio raised $14.5 Million in a Seed round on June 28, 2024.
Who invested in Waypoint Bio?
Fifty Years, Recode Ventures and Hummingbird Ventures are named as investors in this round.
What does Waypoint Bio do?
Waypoint Bio is a biotechnology company pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology.
Where is Waypoint Bio based and how big is it?
Waypoint Bio is based in New York, New York, United States. Fundz records about 21 employees.
Who are the decision-makers at Waypoint Bio?
Fundz holds 1 contact at Waypoint Bio, including the Co-founder and CSO. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Waypoint Bio that raised within 45 days of this round, from Fundz verified event records.

  • IDRx raised $120M (Series B) on August 7, 2024.
  • NeuroTherapia raised $12M (Series B) on August 6, 2024.
  • bioAffinity Technologies raised $450K on August 5, 2024.
  • Lapix Therapeutics raised $2.2M on August 2, 2024.
  • bioAffinity Technologies raised $1.3M on August 2, 2024.
  • Healx raised $47M (Series C) on August 1, 2024.

Who to call at Waypoint Bio, and when

A new round usually means Waypoint Bio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Waypoint Bio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Waypoint Bio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Waypoint Bio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Waypoint Bio

Location

New York, New York, United States

About

Waypoint Bio is a biotechnology company pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology. The company's platform uniquely combines spatial biology with pooled screening for the purpose of drug discovery, enabling the simultaneous measurement of cell therapy candidates' navigation in the solid tumor microenvironment. Waypoint will use its seed financing toward designing CAR T-cell therapies with superior efficacy against the tumor microenvironment, and later, Treg therapies for autoimmune diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Waypoint Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsDavid P., Co-founder and CSO hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Waypoint Bio's next move

See what Strategic adds

Waypoint Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.